Net income
−$4.7M
+27% vs same quarter last year
EPS, diluted
−$0.17
+29.2% vs same quarter last year
Operating cash flow
−$3.4M
+37.7% vs same quarter last year
Operating income
−$5M
+32.6% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $50K | −$46M |
| FY24 | $14K | −$42M |
| FY23 | $155K | −$30M |
| FY22 | $374K | −$27.3M |
| FY21 | $181K | −$30.3M |
| FY20 | $11K | −$12.1M |
| FY19 | - | −$7.7M |
| FY18 | $0 | −$12.4M |
| FY17 | $0 | −$831.5K |
| FY16 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −94766% | −92000% |
| FY24 | −304535.7% | −300000% |
| FY23 | −19187.7% | −19354.8% |
| FY22 | −6938.8% | −7299.2% |
| FY21 | −16106.6% | −16762.4% |
| FY20 | −111163.6% | −109990.9% |
| FY19 | - | - |
| FY18 | - | - |
| FY17 | - | - |
| FY16 | - | - |
- Inmune Bio
- Healthcare median
Show the numbers
| Year | Inmune Bio | Healthcare median |
|---|---|---|
| FY25 | −92000% | −30.6% |
| FY24 | −300000% | −47% |
| FY23 | −19354.8% | −58% |
| FY22 | −7299.2% | −80.4% |
| FY21 | −16762.4% | −71.8% |
| FY20 | −109990.9% | −62.2% |
| FY19 | - | −46.2% |
| FY18 | - | −49.6% |
| FY17 | - | −45.9% |
| FY16 | - | −36% |